Patient preferences for biologic agents in rheumatoid arthritis: A discrete-choice experiment

Value in Health

Volumn 16, Issue 2, 2013, Pages 385-393

  Augustovski, Federico ^a,b   Beratarrechea, Andrea ^a,b   Irazola, Vilma ^a   Rubinstein, Fernando ^a,b   Tesolin, Pablo ^b   Gonzalez, Juan ^c   Lencina, Verónica ^d   Scolnik, Marina ^b   Waimann, Christian ^d   Navarta, David ^b   Citera, Gustavo ^d   Soriano, Enrique R ^b  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c RTI HEALTH SOLUTIONS   (United States)

^d Instituto de Rehabilitación Psicofísica ^*  (Argentina)

Author keywords

adverse effects; arthritis; disease modifying antirheumatic drugs; patient preferences; rheumatoid drug therapy psychology

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; COST; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84875459805     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.11.007     Document Type: Article

References (43)

1. F. Wolfe, and D.J. Hawley The long-term outcomes of rheumatoid arthritis: work disability: a prospective 18-year study of 823 patients J Rheumatol 25 1998 2108 2117
2. A. Young, G. Koduri, and M. Batley Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis Rheumatology (Oxford) 46 2007 350 357
3. J.R. O'Dell Therapeutic strategies for rheumatoid arthritis N Engl J Med 350 2004 2591 2602
4. A. Finckh, M.H. Liang, C.M. van Herckenrode, and P. de Pablo Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis Arthritis Rheum 55 2006 864 872
5. R.F. Meenan, J.H. Mason, and J.J. Anderson AIMS2: the content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire Arthritis Rheum 35 1992 1 10
6. R.B. Landewe, M. Boers, and A.C. Verhoeven COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention Arthritis Rheum 46 2002 347 356
7. J.M. Bathon, R.W. Martin, and R.M. Fleischmann A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586 1593
8. F.C. Breedveld, M.H. Weisman, and A.F. Kavanaugh The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
9. E.W. St Clair, D.M. van der Heijde, and J.S. Smolen Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 2004 3432 3443
10. A.A. Montgomery, and T. Fahey How do patients' treatment preferences compare with those of clinicians? Qual Health Care 10 Suppl. 1 2001 i39 i43
11. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14403-13.
12. M.E. Suarez-Almazor, B. Conner-Spady, and C.J. Kendall Lack of congruence in the ratings of patients' health status by patients and their physicians Med Decis Making 21 2001 113 121
13. J.P. Kassirer Incorporating patients' preferences into medical decisions N Engl J Med 330 1994 1895 1896
14. S.M. Sawyer, and H.J. Fardy Bridging the gap between doctors' and patients' expectations of asthma management J Asthma 40 2003 131 138
15. L. Fraenkel, S. Bogardus, and J. Concato Patient preferences for treatment of rheumatoid arthritis Ann Rheum Dis 63 2004 1372 1378
16. S. Özdemir, F.R. Johnson, and A.B. Hauber Hypothetical bias, cheap talk, and stated willingness to pay for health care J Health Econ 28 2009 894 901
17. L.J. Kay, and I.D. Griffiths UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register Rheumatology (Oxford) 45 2006 1376 1379
18. A. Gibofsky, W.R. Palmer, and J.A. Goldman Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study Curr Med Res Opin 22 2006 169 183
19. Y. Yazici, N. Shi, and A. John Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy Bull NYU Hosp Jt Dis 66 2008 77 85
20. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ 2010 Dec 19 [Epub ahead of print]. Available from: http://onlinelibrary.wiley.com/doi/10.1002/hec. 1697/abstract;jsessionid=9D4332F1B04AA338DB94A1A02CF33FA8.d02t04.
21. J. Hall, P. Kenny, and M. King Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination Health Econ 11 2002 457 465
22. M.T. King, J. Hall, and E. Lancsar Patient preferences for managing asthma: results from a discrete choice experiment Health Econ 16 2007 703 717
23. E.J. Lancsar, J.P. Hall, and M. King Using discrete choice experiments to investigate subject preferences for preventive asthma medication Respirology 12 2007 127 136
24. Z. Hakim, and D.S. Pathak Modelling the EuroQol data: a comparison of discrete choice conjoint and conditional preference modelling Health Econ 8 1999 103 116
25. M. Sculpher, S. Bryan, and P. Fry Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment BMJ 328 2004 382
26. F.C. Arnett, S.M. Edworthy, and D.A. Bloch The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 1988 315 324
27. G. Citera, M.S. Arriola, and J.A. Maldonado-Cocco Validation and crosscultural adaptation of an Argentine Spanish version of the Health Assessment Questionnaire Disability Index J Clin Rheumatol 10 2004 110 115
28. F.A. Augustovski, V.E. Irazola, and A.P. Velazquez Argentine valuation of the EQ-5D health states Value Health 12 2009 587 596
29. E. Lancsar, and J. Louviere Conducting discrete choice experiments to inform healthcare decision making: a user's guide Pharmacoeconomics 26 2008 661 677
30. Orme, B. Sample size issues for conjoint analysis. In: Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research (2nd ed.). Madison, WI: Research Publishers LLC, 2010
31. M. Ryan, K. Gerard, and M.A. Amaya Using discrete choice experiments to value health and health care J. Ian, The Economic of Non Market Goods and Resources 2008 Springer Academic Publishers Netherlands Antilles, AN
32. WH. Greene Econometric Analysis (5th ed.) 2003 Prentice-Hall Upper Saddle River, NJ
33. P. Tugwell, C. Bombardier, and W.W. Buchanan The MACTAR Patient Preference Disability Questionnaire - an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis J Rheumatol 14 1987 446 451
34. P. Tugwell, G. Wells, and V. Strand Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group Arthritis Rheum 43 2000 506 514
35. A.C. Verhoeven, M. Boers, and S. van der Liden Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. The McMaster Toronto Arthritis J Rheumatol 27 2000 2801 2809
36. T. Heiberg, and T.K. Kvien Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority Arthritis Rheum 47 2002 391 397
37. L.J. Mangham, K. Hanson, and B. McPake How to do (or not to do). Designing a discrete choice experiment for application in a low-income country Health Policy Plan 24 2009 151 158
38. E. Lancsar, and J. Louviere Conducting discrete choice experiments to inform healthcare decision making: a user's guide Pharmacoeconomics 26 2008 661 677
39. L. Fraenkel, S. Bogardus, J. Concato, and D. Felson Unwillingness of rheumatoid arthritis patients to risk adverse effects Rheumatology (Oxford) 41 2002 253 261
40. Y. Yazici, B.J. McMorris, and T. Darkow Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis Clin Exp Rheumatol 27 2009 907 913
41. J. Carbonell, and X. Badia Expectations, preferences and satisfaction of patients with rheumatoid arthritis receiving infliximab treatment Med Clin (Barc) 131 2008 493 499
42. R. Lisicki, and L. Chu What matters to patients and physicians when considering biologic therapy for rheumatoid arthritis Postgrad Med 120 2008 154 160
43. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and P.J. Kerstens Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial) Ann Rheum Dis 66 2007 1227 1232